

**60<sup>th</sup> International Conference of  
the Israel Heart Society**  
**April 22, 2013**

**“New Observations on the Role of the  
Autonomic Nervous System in Arrhythmias”**

Douglas P. Zipes, MD

Distinguished Professor

Indiana University School of Medicine

Krannert Institute of Cardiology

Editor-in-Chief *Heart Rhythm*

Conflicts of Interest:  
Co-PI on DEFEAT HF  
No consultant or stock conflicts


# ESTABLISHED CLINICAL SITUATIONS

- 6 am to 12 noon increase in sudden cardiac arrest, stroke, and myocardial infarction (PERHAPS related to increased catecholamine secretion upon arising,
- BUT clock-dependent oscillator, krüppel-like factor 15 (Klf15) transcriptionally controls rhythmic expression of Kv channel-interacting protein 2 (KChIP2), a critical subunit required for generating the transient outward potassium current-(Jeyaraj et al. Nature 483:96, 2012 )
- Increased sudden death in winter months: adults and infants, dogs with MI, Los Angeles or Canada, or Australia (June – August) Is there a seasonal oscillator also? BP, QT (males), and lipids all increase in winter months: SHORT DAYS?
- Increased sudden death after stress such as natural disasters or personal loss


# STRESS INDUCED CARDIOMYOPATHY (Takotsubo)

Typical Electrocardiograms Obtained 24 to 48 Hours after Presentation in Four Patients with


**A Patient 4**




**B Patient 2**



**C Patient 16**



**D Patient 18**




Wittstein et al: Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med*. 2005 Feb 10;352(6):539-48




The NEW ENGLAND  
JOURNAL of MEDICINE



# Acquired long QT from stress cardiomyopathy




# Acquired long QT from stress cardiomyopathy



What are potential mechanisms by which ANS can trigger death? There may be multiple, but let us consider two:


- Autonomic heterogeneity
- Sympathetic discharge

# AUTONOMIC INNERVATION OF THE VENTRICLES



Copyright 2005 by Elsevier Science


# AUTONOMIC INNERVATION OF THE VENTRICLES



Copyright 2005 by Elsevier Science




# AUTONOMIC INNERVATION OF THE VENTRICLES




Copyright 2005 by Elsevier Science

# Sympathetic denervation after myocardial infarction




# Increased stellate ganglion nerve activity (SGNA) preceding ventricular tachycardia




# Sympathetic stimulation increases dispersion of repolarization in humans with MI

compared to normal patients.









# Simultaneous recordings of stellate ganglion and vagal nerve activity and ECG before and after MI show increase SGNA but flat VNA






# Increase in integrated SGNA and ratio SGNA/VNA over 24 hrs after MI show sympathovagal imbalance



# Immunohistochemical staining show increased immunoreactivity in both SG



# WHAT'S NEW IN THERAPIES OF SYMPATHETIC INHIBITION TO REDUCE SCD?










(Some treatments not that new!)



Ann Intern Med. 1968 Mar;68(3):591-7.

# Treatment of ventricular arrhythmia by permanent atrial pacemaker and cardiac sympathectomy.



Zipes DP, Festoff B, Schaal SF, Cox C, Sealy WC, Wallace AG



**Bilateral sympathectomy**




# Left Cardiac Sympathetic Surgical Denervation






# Twelve-Lead Electrocardiograms (ECGs) Obtained from Patient 2 during Exercise Stress Tests before and after Left Cardiac Sympathetic Denervation (LCSD)

A 16 Months before LCSD




CPVT

B 2 Days after LCSD





LCSD

# Video-assisted thoracic surgery




Resection of the lower half of the left stellate ganglion and top 2 or 3 ganglia

For LQT, drug induced (methadone), recurrent ischemic/nonischemic VT



# Relative risks of mortality and morbidity at 30 days post-randomization in EPHEBUS patients with LVEF ≤ 30%

Beta blockers  
Aldosterone inhibitors  
ACE inhibitors  
Surgical interruption SG




**VAGAL STIMULATION CAN BE  
USED TO REGULATE  
SYMPATHETIC EFFECTS:**

Vagal stimulation opposes  
sympathetic action at  
prejunctional (NE release) and  
post junctional (cell) levels



# PET Images in dogs after pacing induced AF: Increased sympathetic innervation



Control

Atrial fibrillation



# Vagal stimulation for atrial fibrillation

- Vagal stimulation is “pro-fibrillatory” in the atrium but anti fibrillatory in the ventricle
- Could low levels of vagal stimulation be anti-sympathetic and be antiarrhythmic?


# Low-Level Vagus Nerve Stimulation

- Low-level vagus nerve stimulation = LL-VNS
- Left-sided cervical vagus nerve
- Stimulus strength: 1 V below the threshold needed to reduce the sinus rate ( $4 \pm 2$  V, range 1-6 V)

Shen et al. Circulation 2011;123:2204-12

# Daily Changes of SGNA

(mV-s)




Baseline

During LL-VNS


After LL-VNS

# Paroxysmal Atrial Tachycardias



**A**



**B**



# Paroxysmal Atrial Fibrillation






# Conclusions


- Chronic LL-VNS reduces SGNA and tyrosine hydroxylase-positive nerve density in the left stellate ganglion.
- It also suppresses the paroxysmal atrial tachyarrhythmias in ambulatory dogs.
- The remodeling in the left stellate ganglion underlies the antiarrhythmic mechanisms of LL-VNS.
- Could this be a new treatment for PAF?

What about chronic vagal  
nerve stimulation for  
ventricular arrhythmias and  
heart failure?

# Increased sympathetic activity affects cardiac, renal, and vascular function



# Chronic right vagal nerve stimulation





# Chronic vagus nerve stimulation for HF


DeFerrari et al European Heart Journal 2011; 32:847

IV

III

II



I






# Chronic vagus nerve stimulation

DeFerrari et al European Heart Journal 2011; 32:847




# Neurostimulation Devices To Modulate Sympathetic Activity

## Spinal cord stimulation





# SCS Implantation

**A**




**B**





# POLYMORPHIC VENTRICULAR TACHYCARDIA-FIBRILLATION







## MONOMORPHIC VENTRICULAR TACHYCARDIA




# Results of Spinal Cord Stimulation



# Research timeline and experimental design




## Stage 2: HR effects




Lopshire et al. Circulation 2009;120:286-294





# Stage 2: BP effects




# Stage 2: Body weight



# Serum markers and neuromodulation




# Neuromodulation in heart failure – LV dimension effects (LVEDD)







# Neuromodulation in heart failure – Ventricular arrhythmias



# Stage 2: Ejection fraction



# Ejection Fraction after SCS (Unpublished)



# CONCLUSIONS

- SCS T1-T4 significantly improved cardiac contractile function and decreased ventricular arrhythmias in a canine model of healed myocardial infarction and heart failure



Determining the Feasibility of  
Spinal Cord Neuromodulation for  
the Treatment of Chronic Heart  
Failure

**DEFEAT-HF**

H. Theres (Europe)

D. Zipes (US)

Principal Investigators

# Spinal Cord Stimulation (SCS) for Heart Failure


## Application

- Spinal Cord Stimulation applied at level of the heart
- No new technology needed

## Evidence

- Hypothesis: SCS reduces cardiac sympathetic drive
- Mixed pre-clinical HF results:
  - Strong results in post-infarct high rate pacing HF model
  - Modest results in micro-embolism HF model

Sympathetic Inhibition  
Parasympathetic Stimulation




From Mann, "Pathophysiology of Heart Failure" in Braunwald's Heart Disease, p543

Autonomic modulation to normalize neural control of the heart and cardiovascular system

# PrimeADVANCED™ SCS Implant



49 mm (1.9")



Model 3777 Octad Percutaneous Lead  
Model 37081 Lead Extension

Model 37702 PrimeADVANCED™ INS

# Study Purpose

Determine feasibility of spinal cord stimulation (SCS) as a chronic therapy for heart failure (HF)

- Single percutaneous lead
- Target: T2-T4 level of the spinal cord



# Study Objectives

## Primary objective:

- To evaluate the reduction in left ventricular end systolic volume index (LVESVi) after 6 months of SCS therapy in the Treatment arm compared to the Control arm

## Secondary objectives:

- To characterize the change in peak oxygen uptake between the Treatment arm and Control arm
- To characterize the change in proBNP between the Treatment arm and Control arm

## Additional Analyses:

- Change in QOL
- Adverse Events
- Frequency of hospitalizations for HF or CV events
- Changes in NYHA functional class
- Holter data analysis

# Key Inclusion Criteria

- LVEF of 35% or less
- NYHA functional Class III at the time of screening
- QRS duration less than 120 ms
- LVEDD of 55 mm – 80 mm
- Stable medical therapy for HF prior to enrollment\*
- Serum creatinine  $\leq 3.0$ mg/dL
- 18 years or older

\* *Stable medical therapy is defined as no increase or decrease greater than 50% for two weeks in diuretics, and no increase greater than 100% or decrease greater than 50% for one month in ACE and ARB and for three months in Beta Blockers*

# Current Status

- 23 sites are actively recruiting patients: U.S., Europe, Canada
- Study goal = 70 successful implants to ensure 60 subjects reach 6 months of follow-up
- Recruitment on schedule and plan to finish in the next several months

# Autonomic modulation trials using class III

Trial	Sponsor	Therapy
INOVATE-HF	BioControl	VNS
NECTAR-HF	BSX	VNS
SCS HEART	STJ	SCS
Neurostimulation of Spinal Nerves That Affect the Heart	The Methodist Hospital System – Dr. Torre	SCS



If successful, VNS directly  
or via spinal cord  
stimulation will reduce VAs  
and improve LV function,  
providing a significant  
advance in treating patients  
with heart failure.

**In summary, many mysteries about sudden death remain to be written and explained.**



**THANK YOU FOR YOUR ATTENTION**

